C4 Therapeutics logo

C4 Therapeutics Share Price Today

(NASDAQ: CCCC)

C4 Therapeutics share price is $1.25 & ₹106.83 as on 18 Apr 2025, 2.30 'hrs' IST

$1.25

0.15

(13.64%)

Market is closed - opens 7 PM, 21 Apr 2025

View live C4 Therapeutics share price in Dollar and Rupees. Guide to invest in C4 Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in C4 Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

C4 Therapeutics share price movements

  • Today's Low: $1.13
    Today's High: $1.29

    Day's Volatility :12.06%

  • 52 Weeks Low: $1.09
    52 Weeks High: $7.66

    52 Weeks Volatility :85.84%

C4 Therapeutics (CCCC) Returns

PeriodC4 Therapeutics, IncSector (Health Care)Index (Russel 2000)
3 Months
-67.53%
-2.8%
0.0%
6 Months
-80.0%
-11.0%
0.0%
1 Year
-81.4%
-1.9%
0.0%
3 Years
-85.84%
-1.5%
-12.9%

C4 Therapeutics (CCCC) Key Statistics

in dollars & INR

Previous Close
$1.1
Open
$1.09
Today's High
$1.285
Today's Low
$1.13
Market Capitalization
$88.7M
Today's Volume
$1.8M
52 Week High
$7.66
52 Week Low
$1.085
Revenue TTM
$35.6M
EBITDA
$-115.4M
Earnings Per Share (EPS)
$-1.52
Profit Margin
-295.96%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-45.58%

How to invest in C4 Therapeutics Stock (CCCC) from India?

It is very easy for Indian residents to invest directly in C4 Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the C4 Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for C4 Therapeutics or CCCC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of C4 Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of C4 Therapeutics shares which would translate to 0.684 fractional shares of C4 Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like C4 Therapeutics, in just a few clicks!

Returns in C4 Therapeutics (CCCC) for Indian investors in Rupees

The C4 Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

C4 Therapeutics investment value today

Current value as on today

₹20,942

Returns

₹79,058

(-79.06%)

Returns from C4 Therapeutics Stock

₹81,399 (-81.4%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards C4 Therapeutics (CCCC)

58%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for C4 Therapeutics Stock from India on INDmoney has increased by 58% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in C4 Therapeutics

  • Soleus Capital Management, L.P.

    9.83%

  • Wasatch Advisors LP

    8.55%

  • BlackRock Inc

    7.83%

  • RA Capital Management, LLC

    6.87%

  • Orbimed Advisors, LLC

    6.17%

  • Morgan Stanley - Brokerage Accounts

    5.41%

Analyst Recommendation on C4 Therapeutics

Rating
Trend

Buy

    73%Buy

    26%Hold

    0%Sell

Based on 15 Wall street analysts offering stock ratings for C4 Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on C4 Therapeutics Stock (CCCC)

What analysts predicted

Upside of 1185.71%

Target:

$16.07

Current:

$1.25

Insights on C4 Therapeutics Stock (Ticker Symbol: CCCC)

  • Price Movement

    In the last 7 days, CCCC stock has moved down by -11.3%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 15.36M → 5.17M (in $), with an average decrease of 66.3% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -17.71M → -34.57M (in $), with an average decrease of 39.7% per quarter
  • CCCC vs ONC (1 yr)

    In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 159.7%
  • CCCC vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 117.2%
  • Price to Sales

    ForCCCC every $1 of sales, investors are willing to pay $2.4, whereas for Beone Medicines Ltd, the investors are paying $6.4 for every $1 of sales.

C4 Therapeutics Technicals Summary

Sell

Neutral

Buy

C4 Therapeutics is currently in a neutral trading position according to technical analysis indicators.

C4 Therapeutics (CCCC) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
C4 Therapeutics, Inc logo
-49.77%
-80.0%
-81.4%
-85.84%
-95.1%
Regeneron Pharmaceuticals, Inc. logo
-17.1%
-41.85%
-37.2%
-21.74%
-0.85%
Beone Medicines Ltd logo
-13.12%
5.03%
78.34%
40.23%
43.44%
Vertex Pharmaceuticals Incorporated logo
-4.76%
2.3%
24.05%
71.43%
78.99%
Alnylam Pharmaceuticals, Inc. logo
-9.09%
-19.67%
62.43%
39.66%
61.91%

About C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Organization
C4 Therapeutics
Employees
110
CEO
Mr. Andrew J. Hirsch M.B.A.
Industry
Health Technology

Management People of C4 Therapeutics

NameTitle
Mr. Andrew J. Hirsch M.B.A.
CEO, President & Director
Dr. Kenneth C. Anderson M.D., Ph.D.
Co-Founder, Independent Director & Member of Scientific Advisory Board
Dr. Stewart Fisher Ph.D.
Consultant
Dr. Leonard M. J. Reyno M.D.
Chief Medical Officer
Dr. Nathanael S. Gray Ph.D.
Co-Founder & Member of Scientific Advisory Board
Ms. Kendra Adams
CFO & Treasurer
Mr. Mark Mossler
Chief Accounting Officer
Ms. Paige Mahaney Ph.D.
Chief Scientific Officer
Ms. Courtney Solberg
Senior Manager of Investor Relations
Ms. Jolie M. Siegel J.D.
Chief Legal Officer & Corporate Secretary

Important FAQs about investing in CCCC Stock from India :

What is C4 Therapeutics share price today?

C4 Therapeutics share price today stands at $1.25, Open: $1.09 ; Previous Close: $1.10 ; High: $1.29 ; Low: $1.13 ; 52 Week High: $7.66 ; 52 Week Low: $1.09.

The stock opens at $1.09, after a previous close of $1.10. The stock reached a daily high of $1.29 and a low of $1.13, with a 52-week high of $7.66 and a 52-week low of $1.09.

Can Indians buy C4 Therapeutics shares?

Yes, Indians can invest in the C4 Therapeutics (CCCC) from India.

With INDmoney, you can buy C4 Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy C4 Therapeutics at zero transaction cost.

How can I buy C4 Therapeutics shares from India?

It is very easy to buy C4 Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of C4 Therapeutics (CCCC) be purchased?

Yes, you can buy fractional shares of C4 Therapeutics with INDmoney app.

What are the documents required to start investing in C4 Therapeutics stocks?

To start investing in C4 Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of C4 Therapeutics Stock (CCCC)?

Today’s highest price of C4 Therapeutics (CCCC) is $1.29.

Today’s lowest price of C4 Therapeutics (CCCC) is $1.13.

What is today's market capitalisation of C4 Therapeutics?

Today's market capitalisation of C4 Therapeutics CCCC is 88.7M

What is the 52 Week High and Low Range of C4 Therapeutics Stock (CCCC)?

  • 52 Week High

    $7.66

  • 52 Week Low

    $1.09

What are the historical returns of C4 Therapeutics (CCCC)?

  • 1 Month Returns

    -49.77%

  • 3 Months Returns

    -80%

  • 1 Year Returns

    -81.4%

  • 5 Years Returns

    -95.1%

Who is the Chief Executive Officer (CEO) of C4 Therapeutics ?

Mr. Andrew J. Hirsch M.B.A. is the current Chief Executive Officer (CEO) of C4 Therapeutics.